U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H14N2
Molecular Weight 198.2637
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TACRINE

SMILES

NC1=C2C=CC=CC2=NC3=C1CCCC3

InChI

InChIKey=YLJREFDVOIBQDA-UHFFFAOYSA-N
InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)

HIDE SMILES / InChI
Molecular Formula C13H14N2
Molecular Weight 198.2637
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/cognex.html

Tacrine is a parasympathomimetic- a reversible cholinesterase inhibitor that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine at cholinergic synapses through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process. The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine. is used for the palliative treatment of mild to moderate dementia of the Alzheimer's type. Tacrine was marketed under the trade name Cognex. Because of its liver toxicity and attendant requirement for monitoring liver function, tacrine prescriptions dropped after other acetylcholinesterase inhibitors were introduced, and its use has been largely discontinued.

CNS Activity

Originator

Warner-Lambert
23
Curator's Comment: Originally developed by Warner-Lambert Co.

Approval Year

1993
136
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 500.0 nM [IC50]
Inhibitor
8297
 23.0 nM [IC50]
Inhibitor
8297
 0.46 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Cognex

Approved Use

Cognex® (tacrine hydrochloride capsules) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

Launch Date

1993
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.8 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7836549
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TACRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
91.8 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7836549
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TACRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.8 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7836549
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TACRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
n = 64
Health Status: unhealthy
Condition: Alzheimer's disease
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Population Size: 64
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (21 patient)
Vomiting (21 patient)
Anorexia (21 patient)
Dyspepsia (21 patient)
Diarrhea (21 patient)
Abdominal pain (21 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 146
Health Status: unhealthy
Age Group: adult
Population Size: 146
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Disc. AE: Transaminases increased, Atrial fibrillation...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Atrial fibrillation (1 patient)
Dyspnea (1 patient)
Chest pain (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 150
Health Status: unhealthy
Age Group: adult
Population Size: 150
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Disc. AE: Transaminases increased, Nausea...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Nausea (1 patient)
Vomiting (1 patient)
Pallor (1 patient)
Vasodilatation (1 patient)
Sweating increased (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
n = 64
Health Status: unhealthy
Condition: Alzheimer's disease
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Population Size: 64
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Anorexia 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
n = 64
Health Status: unhealthy
Condition: Alzheimer's disease
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Population Size: 64
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Diarrhea 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
n = 64
Health Status: unhealthy
Condition: Alzheimer's disease
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Population Size: 64
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Dyspepsia 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
n = 64
Health Status: unhealthy
Condition: Alzheimer's disease
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Population Size: 64
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Nausea 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
n = 64
Health Status: unhealthy
Condition: Alzheimer's disease
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Population Size: 64
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Vomiting 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
n = 64
Health Status: unhealthy
Condition: Alzheimer's disease
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Population Size: 64
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Atrial fibrillation 1 patient
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 146
Health Status: unhealthy
Age Group: adult
Population Size: 146
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Chest pain 1 patient
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 146
Health Status: unhealthy
Age Group: adult
Population Size: 146
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Dyspnea 1 patient
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 146
Health Status: unhealthy
Age Group: adult
Population Size: 146
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Transaminases increased 1 patient
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 146
Health Status: unhealthy
Age Group: adult
Population Size: 146
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Nausea 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 150
Health Status: unhealthy
Age Group: adult
Population Size: 150
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Pallor 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 150
Health Status: unhealthy
Age Group: adult
Population Size: 150
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Sweating increased 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 150
Health Status: unhealthy
Age Group: adult
Population Size: 150
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Transaminases increased 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 150
Health Status: unhealthy
Age Group: adult
Population Size: 150
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Vasodilatation 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 150
Health Status: unhealthy
Age Group: adult
Population Size: 150
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Vomiting 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
unhealthy, adult
n = 150
Health Status: unhealthy
Age Group: adult
Population Size: 150
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Page: p. 5
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1054

OCT1
327

OCT3
80

OCTN2
50

P-gp
1537
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
1537
 inconclusive
CYP1A2
1054
 yes
OCT1
327
 yes
OCT3
80
 yes
OCTN2
50
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:45980
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45980
ChemicalBook
CB7699634
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7699634
MolPort
MolPort-000-881-472
https://www.molport.com/shop/molecule-link/MolPort-000-881-472
ZINC
ZINC000019014866
http://zinc15.docking.org/substances/ZINC000019014866
eMolecules
872890
https://www.emolecules.com/cgi-bin/more?vid=872890
PubMed

PubMed

TitleDatePubMed
An appraisal of tacrine-extended suxamethonium.
1970 Feb
Suxamethonium apnoea masked by tetrahydroaminacrine.
1978 Jul-Aug
Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes.
1989 Nov 28
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats.
1992
Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat.
1993 Mar
Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats.
1993 Nov 30
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
1995 Aug
Systemic administration of lithium chloride and tacrine but not kainic acid augments citrulline content of rat brain.
1995 Dec 27
Delirium caused by tacrine and ibuprofen interaction.
1996 Jun
Convulsive effects of tacrine.
1996 May 11
Adverse interaction of tacrine and haloperidol.
1996 Nov
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.
2002 Dec
In vitro inactivation of rat brain acetylcholinesterase by DSP-4 and its derivatives OS-21 and OS-23 and protective activity of tacrine (9-amino-1,2,3,4-tetrahydroacridine).
2005
Pharmacological characterization of orally active cholinesterase inhibitory activity of Prunus persica L. Batsch in rats.
2006
In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
2006 Jul
Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7.
2006 May
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease.
2006 Oct 25
Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.
2007
Long-term tetrahydroaminoacridine treatment and quantitative EEG in Alzheimer's disease.
2007
Current therapeutic options for Alzheimer's disease.
2007 Dec
WITHDRAWN: Tacrine for Alzheimer's disease.
2007 Jul 18
Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.
2007 Jul 25
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.
2007 Jun
Allosteric modulation of muscarinic acetylcholine receptors.
2007 Sep
Hepatoprotective effect of Cirsium arisanense Kitamura in tacrine-treated hepatoma Hep 3B cells and C57BL mice.
2008
Effects of zonisamide on experimental tremors in rats.
2008
The investigation of structure-activity relationships of tacrine analogues: electronic-topological method.
2008 Aug 6
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.
2008 Dec
Dose-related effects of the acetylcholinesterase inhibitor tacrine on cocaine and food self-administration in rats.
2008 Jan
Cholinesterase inhibitors for delirium.
2008 Jan 23
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
2008 Jun 12
1-Phenyl-6,7,8,9-hexa-hydro-1H,5H-cyclo-hepta-[1',2':2,3]pyrido[6,5-c]pyrazol-4-amine: a new tacrine analogue.
2008 May 10
The protective effect of the cholinergic anti-inflammatory pathway against septic shock in rats.
2008 Oct
Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase.
2008 Oct 15
Comparison studies of tacrine and bis7-tacrine on the suppression of scopolamine-induced behavioral changes and inhibition of acetylcholinesterase in mice.
2009
Cholinergic influence on memory stages: A study on scopolamine amnesic mice.
2009 Aug
Rapid determination of tacrine and other drug metabolites in microsomal incubate by newly developed targeting algorithm on UHPLC/TOFMS.
2009 Dec 15
Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.
2009 Feb 6
Determination of basic azaarenes in aviation kerosene by solid-phase extraction and HPLC-fluorescence detection.
2009 Jun
An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells.
2009 Jun 1
Long-lasting decreases in cocaine-reinforced behavior following treatment with the cholinesterase inhibitor tacrine in rats selectively bred for drug self-administration.
2009 Nov
Coupling an HCN2-expressing cell to a myocyte creates a two-cell pacing unit.
2009 Nov 1
Contribution of the d-Serine-Dependent Pathway to the Cellular Mechanisms Underlying Cognitive Aging.
2010
Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine.
2010
A second-generation device for automated training and quantitative behavior analyses of molecularly-tractable model organisms.
2010 Dec 17
A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.
2010 Jan 18
Dual-acting drugs: an in vitro study of nonimidazole histamine H3 receptor antagonists combining anticholinesterase activity.
2010 Jul 5
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
2013 Dec
Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors.
2013 Mar 25
Patents

Patents

05013741
3
JP2003512428A
9
JP2004315496A
25
JP2007508336A
3
JP4722295B2
104
JPH0366670A
3
JPH0820577A
3

Sample Use Guides

In Vivo Use Guide
Oral Initially, 10 mg 4 times daily for at least 4 weeks. If well tolerated and increased serum ALT concentrations have not occurred, increase dosage to 20 mg 4 times daily; if tolerated, increase dosage in 40-mg daily increments (divided into 4 doses daily) at 4-week intervals up to a maximum of 160 mg daily (40 mg 4 times daily).
Route of Administration: Oral
In Vitro Use Guide
Tacrine (0.01-10 uM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT (IC50 values were 0.46 and 0.70 uM vs. 0.29 uM, respectively).
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:45:20 GMT 2023
Edited
by admin
on Sat Dec 16 16:45:20 GMT 2023
Record UNII
4VX7YNB537
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TACRINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
TACRINAL
Brand Name English
Tacrine [WHO-DD]
Common Name English
TACRINE [VANDF]
Common Name English
tacrine [INN]
Common Name English
TACRINE [MI]
Common Name English
9-AMINO-1,2,3,4-TETRAHYDROACRIDINE
Systematic Name English
Classification Tree Code System Code
WHO-ATC N06DA01
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
NDF-RT N0000175723
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
WHO-VATC QN06DA01
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
NDF-RT N0000000177
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
NCI_THESAURUS C47792
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
LIVERTOX NBK547868
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID1037272
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
CHEBI
45980
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL95
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
PUBCHEM
1935
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
NCI_THESAURUS
C61961
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
MERCK INDEX
m10424
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY Merck Index
IUPHAR
6687
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
RXCUI
10318
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY RxNorm
SMS_ID
100000082994
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-291-2
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
EVMPD
SUB10796MIG
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
FDA UNII
4VX7YNB537
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
DRUG CENTRAL
2551
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
INN
800
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
CAS
321-64-2
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
MESH
D013619
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
WIKIPEDIA
TACRINE
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
DRUG BANK
DB00382
Created by admin on Sat Dec 16 16:45:22 GMT 2023 , Edited by admin on Sat Dec 16 16:45:22 GMT 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 1A1
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Histamine N-methyltransferase
OFF-TARGET->INHIBITOR
HNMT inhibitors may increase histamine levels in peripheral tissues and exacerbate histamine-related diseases, such as allergic rhinitis, urticaria, and peptic ulcer disease. However, the effect of HNMT inhibitors on brain function is not yet fully understood. Some studies suggest that an increase in brain histamine levels by novel HNMT inhibitors could contribute to the improvement of brain disorders.
IC50
ACETYLCHOLINESTERASE HUMAN
TARGET -> INHIBITOR
IC50
ACETYLCHOLINESTERASE HUMAN
TARGET -> INHIBITOR
IC50
ALDEHYDE OXIDASE
METABOLIC ENZYME -> INHIBITOR
IC50
Structure of TACRINE HYDROCHLORIDE MONOHYDRATE
SALT/SOLVATE -> PARENT
Structure of TACRINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
Structure of 3-HYDROXYTACRINE
METABOLITE -> PARENT
URINE
Structure of VELNACRINE
METABOLITE ACTIVE -> PARENT
URINE
Structure of 4-HYDROXYTACRINE
METABOLITE -> PARENT
URINE
Structure of 9-AMINO-1,2,3,4-TETRAHYDRO-1,3-ACRIDINEDIOL
METABOLITE -> PARENT
URINE
Structure of 2-HYDROXYTACRINE
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of TACRINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966